View as an RSS Feed
View Derek Lowe's Articles BY TICKER:
ABBV, ABT, ACOR, AFFY, ALNY, AMGN, ARIA, ARNA, ASTX, AVEO, AZN, BIIB, BIND, BMS, BTIM, CBST, CEPH, CNCE, CPRX, DNDN, ELN, ESALY, EXEL, GALE, GE, GNBT, GNVC, GS, GSK, ITMN, JNJ, KVPBQ, LLY, MDVN, MEDX, MNKD, MRK, MTXX, MYGN, NTMD, NVO, NVS, NWBO, OSIR, OSUKF, PFE, PTCT, RBXLF, RBXZF, RDEA, REGN, RHHBY, RNN, RUK, SEPR, SGP, SHPG, SNSS, SNY, SQNM, SVNTQ, TKPHF, TRGT, VNDA, VSTM, WYE
- Is Carl Icahn Going for Genzyme?
- The Real Reason for Lilly's R&D Outsourcing
- Read the Novartis / Alcon Fine Print
- Pfizer's Apo-A1 Milano Flop: Typical for Big Pharma Deals
- GE Healthcare's Shameful Libel Suit
- The Historical Success of Growing Big Pharma from Small
- Pfizer's R&D: Spending vs. Productivity
- Do Pfizer's Layoffs Comply with New York Law?
- Competition in Blood - Thinners: Win - Win for Everyone Involved
- Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck
- Pfizer's Chemistry Head Count: Lower than Before the Wyeth Merger
- Another Look at Pfizer's Recent Moves
- Pfizer's New Look
- The Real Price of Big Pharma's Huge Fines
- J&J's New Acquisition Strategy Makes Sense
8 Red Flags of New Biotechs
Oct. 22, 2009 • Comment!
- Pfizer's People Aren't to Blame
- Pfizer: What It Will Look Like a Year from Now
- Which Pfizer / Wyeth Sites Will Shut Down?
- Big Pharma's Future Death Spiral?
- Eli Lilly Braces for Reorganization Moves
- Pfizer Whistle-Blowing: The How and Why
- Sepracor's Suitor Is Hard to Understand
- Justice Department Makes 2.3 Billion Dollar Example of Pfizer's Marketing Practices
- Forest Lab's Hard Sell of Anti-Depressant Raises Questions
- Don't Bury Ariad's Patent Yet
- Eli Lilly's Osteoporosis Drug Stopped in Its Tracks
- Animal Rights Activists Take Anti-Novartis Protest Too Far
- Wyeth Should Be More Forthcoming with Authorship Disclosures
Drug Companies vs. R&D?
Aug. 6, 2009 • 1 Comment
- Savient's Nasty Gout Surprise
- Hoping Against Hope for Wyeth / Elan Alzheimer Dug